Abstract
Background:
The treatment of moderate to severe chronic hand dermatitis (CHD) has been advanced with the introduction of alitretinoin (9-cis-retinoic acid). Although clinical trial data demonstrated the efficacy and safety of alitretinoin, real-world experience is lacking in a more generalized patient population.
Objective:
Patients with CHD often, and unsuccessfully, attempt several therapeutic options before seeing a dermatologist. This chart review study aimed to examine the experience of using alitretinoin for CHD in a dermatology office setting.
Methods:
A retrospective chart review of electronic medical records was conducted of all patients prescribed alitretinoin in a community dermatology practice.
Results:
Alitretinoin was well tolerated in this patient population of 53 patients and showed a clinically significant reduction in disease symptoms.
Conclusion:
Alitretinoin was a safe and well-tolerated treatment with significant clinical improvement in our patient population. Few clinically significant laboratory abnormalities were identified, and only one patient discontinued therapy due to adverse events.
Get full access to this article
View all access options for this article.